Abstract
Interferon regulatory factor 5 (IRF5) is widely recognized as a risk locus for systemic lupus erythematosus (SLE). Risk gene and IRF5 activation is triggered through toll-like receptor signaling. In myeloid cells, this leads to production of type I interferon and inflammatory cytokines, with enhanced production in cells of individuals harboring IRF5 risk alleles. Mouse models have also demonstrated the importance of IRF5 in B cell function, particularly plasma cell differentiation and isotype switching. Here, we evaluated the major SLE risk haplotype of IRF5 on the functional attributes of freshly isolated B cells from human subjects who do not have evidence of SLE or other forms of autoimmunity. We took this approach to avoid the complications of studying genotype-phenotype relationships in B cells that have been chronically exposed to an inflammatory disease environment before isolation. We focused on B cell endophenotypes that included gene expression, antibody secretion, class switching, and apoptotic susceptibility. We performed IRF5 overexpression studies, genetic reporter assays and electro-mobility shift assays on B and myeloid cell lines. Somewhat surprisingly, the results of our analyses indicate that IRF5 risk genotypes do not have a B cell intrinsic effect on these B cell functions. By contrast, we confirmed that the IRF5 risk and non-risk haplotypes exert differential effects in myeloid cells, including an increased susceptibility to apoptosis conferred by the risk haplotype. We also demonstrated an increased binding of the transcription factor specificity protein 1 to an insertion/deletion present in the risk haplotype. Our findings raise the specter that genetic risk alleles can have complex and unexpected lineage-specific effects, and these must be carefully considered when guiding or developing therapies based on understanding disease risk haplotypes.
Highlights
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a breach in B cell tolerance to self-antigens
interferon regulatory factor 5 (IRF5) Expression Is Higher in Monocytes and IgD− Memory B Cell Subsets Independent of Haplotype In SLE, B cell tolerance checkpoints are compromised [37], and it has been shown that SLE risk alleles can affect those tolerance checkpoints
To address whether the IRF5 risk haplotype might affect B cell tolerance, we first asked whether IRF5 expression differs across B cell subsets and whether the risk and non-risk haplotypes are differentially regulated as expression quantitative trait loci
Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a breach in B cell tolerance to self-antigens. The transcription factor interferon regulatory factor 5 (IRF5) is one of approximately 100 genes with SLE-associated risk variants [1, 2]. IRF5 is expressed in myeloid cells and lymphocytes [3,4,5]. IRF5 can be activated by toll-like receptor (TLR) agonists, including nucleic acid-containing immune complexes present in SLE. IFNα can contribute to B cell autoreactivity seen in SLE. Many SLE patients have elevated levels of serum IFNα and markedly increased expression of interferon-inducible genes [9,10,11,12]. Prior studies have shown that SLE-associated risk alleles of IRF5 display increased expression in myeloid cells and influence monocyte and macrophage activation [8, 13, 14]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.